Royalty Pharma (RPRX) Cash from Operations (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Cash from Operations data on file, last reported at 718233000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 20.49% year-over-year to 718233000.0; the trailing twelve-month figure through Mar 2026 stood at 2611980000.0 (down 3.28% YoY), and the FY2025 full-year result was 2489823000.0, down 10.08% from the prior year.
• Cash from Operations slipped to 718233000.0 in Q1 2026, from 827148000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1033837000.0 in Q1 2023 to a low of 363984000.0 in Q2 2025.
• A 5-year average of 653460235.29 and a median of 658209000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 124.62% in 2023 and plunged 44.7% in 2025, its largest moves.
• Tracing RPRX's Cash from Operations over 5 years: stood at 569931000.0 in 2022, then soared by 35.57% to 772628000.0 in 2023, then dropped by 3.9% to 742525000.0 in 2024, then gained by 11.4% to 827148000.0 in 2025, then slipped by 13.17% to 718233000.0 in 2026.
• Business Quant data shows RPRX's Cash from Operations at 718233000.0 in Q1 2026, 827148000.0 in Q4 2025, and 702615000.0 in Q3 2025.